Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 511-520 of 2400 for

Edit search filters
  1. A Study Using Avelumab in Non-Small Cell Lung Cancer that has Progressed

    Scottsdale/Phoenix, AZ

  2. Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

    Rochester, MN

  3. A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer

    Rochester, MN

  5. A Study to Evaluate Hepcidin Mimetic in Patients With Polycythemia Vera

    Scottsdale/Phoenix, AZ

  6. Study of Cabozantinib Combined With Atezolizumab Vs. Second Novel Hormonal Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer

    Rochester, MN

  7. A Study to Evaluate Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  8. A Study to Evaluate A Resilient Living Program for Patients with Advancer Cancer and Their Caregivers

    Rochester, MN

  9. Study of ISB 1342, a CD38/​CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

    Rochester, MN

  10. Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

    Rochester, MN, Jacksonville, FL

.

Mayo Clinic Footer